Istodax
Drug
Celgene Corporation
Total Payments
$1.2M
Transactions
83
Doctors
34
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $70,598 | 5 | 0 |
| 2019 | $362,522 | 13 | 6 |
| 2018 | $534,598 | 17 | 6 |
| 2017 | $264,790 | 48 | 22 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 49 | 98.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,502 | 16 | 1.3% |
| Food and Beverage | $402.41 | 18 | 0.0% |
Payments by Type
Research
$1.2M
49 transactions
General
$16,904
34 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| RM-CL-PTCL-PI-003567 - A Phase 1/2A Study of the Oral 5-Azacytidine In Combination With the Histone Deacetylase Inhibitor Romidepsin For the Treatment of Patients with Relapsed and Refractory Lymphoma | Celgene Corporation | $222,159 | 0 |
| A Phase 1/2A Study of the Oral 5-Azacytidine In Combination With the Histone Deacetylase Inhibitor Romidepsin For the Treatment of Patients with Relapsed and Refractory Lymphoma (RM-CL-PTCL-PI-003567) | Celgene Corporation | $179,706 | 0 |
| RM-CL-BRST-PI-002783 - Phase I/II trial of Cisplatin Romidepsin and Nivolumab in Metastatic Triple Negative Breast Cancer or BRCA Mutation Associated Locally Recurrent or Metastatic Breast Cancer. | Celgene Corporation | $176,698 | 0 |
| A phase II study of maintenance therapy with romidepsin following high dose therapy and autologous stem cell rescue for the treatment of peripheral T-cell non-Hodgkin lymphomas (RM-PTCL-PI-0022) | Celgene Corporation | $121,976 | 0 |
| RM-CL-PTCL-PI-13023 - Romidepsin Therapy in Conditioning and Maintenance in Patients with T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant | Celgene Corporation | $80,608 | 0 |
| RM-CL-BRST-PI-002783 | Celgene Corporation | $72,616 | 0 |
| Phase I/II trial of Cisplatin Romidepsin and Nivolumab in Metastatic Triple Negative Breast Cancer or BRCA Mutation Associated Locally Recurrent or Metastatic Breast Cancer. | Celgene Corporation | $51,510 | 0 |
| RM-PTCL-PI-0028 | Celgene Corporation | $47,663 | 0 |
| RM-CTCL-PI-0012 - A multi-center phase I dose-finding and preliminary efficacy study of the histone deacetylase inhibitor romidepsin (Istodax) in combination with doxorubicin HCI liposomal (Doxil) for the treatment of | Celgene Corporation | $45,350 | 0 |
| RM-CTCL-PI-0012 | Celgene Corporation | $44,916 | 0 |
| Phase I/II trial of Cisplatin Romidepsin and Nivolumab in Metastatic Triple Negative Breast Cancer or BRCA Mutation Associated Locally Recurrent or Metastatic Breast Cancer. (RM-CL-BRST-PI-002783) | Celgene Corporation | $30,764 | 0 |
| RM-NHL-PI-0023 | Celgene Corporation | $29,813 | 0 |
| Romidepsin Therapy in Conditioning and Maintenance in Patients With T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant (RM-CL-OTHER-PI-005336) | Celgene Corporation | $26,002 | 0 |
| GPI-04-0001 | Celgene Corporation | $12,665 | 5 |
| RM-OTHER-CTEP-0033 | Celgene Corporation | $9,006 | 0 |
| Phase II Study of Romidepsin plus Lenalidomide as frontline therapy for patients with untreated PTCL | Celgene Corporation | $8,723 | 0 |
| RM-NHL-PI-0010 | Celgene Corporation | $8,417 | 0 |
| RM-CL-PTCL-PI-003567 | Celgene Corporation | $7,652 | 0 |
| A Phase 1/2A Study of the Oral 5-Azacytidine In Combination With the Histone Deacetylase Inhibitor Romidepsin For the Treatment of Patients with Relapsed and Refractory Lymphoma | Celgene Corporation | $7,100 | 0 |
| RM-NHL-PI-0010 - Phase I/II Study of the Novel Anti-folate Pralatrexate in Combination with the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients with Relapsed and Refractory Lymphoid Malignancies | Celgene Corporation | $6,993 | 0 |
Top Doctors Receiving Payments for Istodax
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $1.2M | 40 |
| , MD | Dermatology | Rochester, NY | $3,346 | 3 |
| , MD, PHD | Dermatology | Duarte, CA | $3,346 | 3 |
| , M.D | Anatomic Pathology & Clinical Pathology | Cleveland, OH | $2,768 | 2 |
| , MD PHD | Anatomic Pathology & Clinical Pathology | Houston, TX | $2,768 | 2 |
| , D.O | Student in an Organized Health Care Education/Training Program | Cleveland, OH | $2,768 | 2 |
| , M.D | Hematology & Oncology | Houston, TX | $2,768 | 2 |
| , MD | Medical Oncology | Bethesda, MD | $2,533 | 1 |
| , MD | Dermatology | Stanford, CA | $2,533 | 1 |
| , M.D | Medical Oncology | New York, NY | $2,533 | 1 |
| , M.D | Internal Medicine | Boston, MA | $2,533 | 1 |
| , M.D | Dermatology | Houston, TX | $2,533 | 1 |
| , MD | Hematology | Oklahoma City, OK | $1,384 | 1 |
| , M.D | Hematology | Hackensack, NJ | $578.00 | 1 |
| , M.D | Hematology | Hackensack, NJ | $578.00 | 1 |
| , MD | Hematology & Oncology | Hackensack, NJ | $578.00 | 1 |
| , MD | Hematology | Hackensack, NJ | $578.00 | 1 |
| , M.D, PHD | Hematology & Oncology | Morristown, NJ | $578.00 | 1 |
| , M.D | Neurology | Charleston, WV | $154.95 | 1 |
| , MD | Medical Oncology | Philadelphia, PA | $42.55 | 1 |
| , MD | Hematology | Lecanto, FL | $24.09 | 1 |
| , M.D | Dermatology | Santurce, PR | $21.04 | 2 |
| Moon Fenton | Hematology & Oncology | Germantown, TN | $16.43 | 1 |
| , M.D | Medical Oncology | Germantown, TN | $16.43 | 1 |
| , MD | Hematology & Oncology | Memphis, TN | $16.43 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $1.2M
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 34
- Transactions 83
About Istodax
Istodax is a drug associated with $1.2M in payments to 34 healthcare providers, recorded across 83 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2020. In 2020, $70,598 was paid across 5 transactions to 0 doctors.
The most common payment nature for Istodax is "Unspecified" ($1.2M, 98.6% of total).
Istodax is associated with 20 research studies, including "RM-CL-PTCL-PI-003567 - A Phase 1/2A Study of the Oral 5-Azacytidine In Combination With the Histone Deacetylase Inhibitor Romidepsin For the Treatment of Patients with Relapsed and Refractory Lymphoma" ($222,159).